Last Update

2004-08-11T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Bradley Zerler?

Dr. Bradley Zerler

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Vice President, Business Development, Vice President, Research

CollaGenex Pharmaceuticals , Inc.

Director of Research

CollaGenex Pharmaceuticals , Inc.

Director of Biology

Locus Pharmaceuticals Inc

Bayer AG

Education

PhD

Web References (14 Total References)


CollaGenex Pharmaceuticals, Inc. Investor Relations

www.corporate-ir.net [cached]

and Strategic Planning, and Brad Zerler, the Company's Vice President of Research.These options were granted without stockholder approval pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) under the

...
40,000, non-qualified stock options to Mr. Zerler, each with exercise


CollaGenex Pharmaceuticals, Inc. Investor Relations

www.corporate-ir.net [cached]

CollaGenex Pharmaceuticals Appoints J. Gregory Ford as VP, Business Development, and Bradley Zerler, PhD, as VP, ResearchCollaGenex Pharmaceuticals, Inc.

...
CollaGenex Pharmaceuticals Appoints J. Gregory Ford as VP, Business Development, and Bradley Zerler, PhD, as VP, Research
NEWTOWN, Pa., Aug 10, 2004 (BUSINESS WIRE) -- CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced the appointments of J. Gregory Ford as Vice President, Business Development and Strategic Planning, and Bradley Zerler, PhD, as Vice President, Research.
...
"The addition of Greg Ford and Brad Zerler will further strengthen our management team as we continue to focus on additional opportunities to leverage our technology platforms and our dedicated dental and dermatology sales forces," stated Colin Stewart, president and chief executive officer of CollaGenex.
...
Brad will oversee our preclinical research and development efforts and play a leading role in protecting and expanding our intellectual property.
...
Bradley Zerler, PhD, as Vice President, Research
Dr. Zerler brings more than 15 years of research and development experience at domestic and international life sciences companies.He will work with Klaus Theobald, M.D., the Company's senior vice president and chief medical officer, to develop future products emerging from CollaGenex's proprietary drug development efforts.
Prior to re-joining CollaGenex, Dr. Zerler was Director of Biology for Locus Pharmaceuticals, Inc., a privately held pharmaceutical company focused on developing novel, small molecule therapeutic drugs.Dr. Zerler worked for CollaGenex from 1997 through 2001 as Director of Research, when the Company launched its flagship product, Periostat(R), the first and only systemic treatment for adult periodontitis.Dr. Zerler initially joined CollaGenex from Bayer where he spent more than 10 years in its Biotechnology and Research divisions.


CollaGenex Pharmaceuticals Appoints J. ...

phx.corporate-ir.net [cached]

CollaGenex Pharmaceuticals Appoints J. Gregory Ford as VP, Business Development, and Bradley Zerler, PhD, as VP, Research

NEWTOWN, Pa., Aug 10, 2004 (BUSINESS WIRE) -- CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced the appointments of J. Gregory Ford as Vice President, Business Development and Strategic Planning, and Bradley Zerler, PhD, as Vice President, Research.
...
"The addition of Greg Ford and Brad Zerler will further strengthen our management team as we continue to focus on additional opportunities to leverage our technology platforms and our dedicated dental and dermatology sales forces," stated Colin Stewart, president and chief executive officer of CollaGenex.
...
Brad will oversee our preclinical research and development efforts and play a leading role in protecting and expanding our intellectual property.
...
Bradley Zerler, PhD, as Vice President, Research
Dr. Zerler brings more than 15 years of research and development experience at domestic and international life sciences companies.He will work with Klaus Theobald, M.D., the Company's senior vice president and chief medical officer, to develop future products emerging from CollaGenex's proprietary drug development efforts.
Prior to re-joining CollaGenex, Dr. Zerler was Director of Biology for Locus Pharmaceuticals, Inc., a privately held pharmaceutical company focused on developing novel, small molecule therapeutic drugs.Dr. Zerler worked for CollaGenex from 1997 through 2001 as Director of Research, when the Company launched its flagship product, Periostat(R), the first and only systemic treatment for adult periodontitis.Dr. Zerler initially joined CollaGenex from Bayer where he spent more than 10 years in its Biotechnology and Research divisions.


CollaGenex Pharmaceuticals Appoints J. Gregory Ford as VP, Business Development, and Bradley Zerler, PhD, as VP, Research

biz.yahoo.com [cached]

CollaGenex Pharmaceuticals Appoints J. Gregory Ford as VP, Business Development, and Bradley Zerler, PhD, as VP, Research

...
NEWTOWN, Pa.--(BUSINESS WIRE)--Aug. 10, 2004--CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI - News) today announced the appointments of J. Gregory Ford as Vice President, Business Development and Strategic Planning, and Bradley Zerler, PhD, as Vice President, Research.
...
"The addition of Greg Ford and Brad Zerler will further strengthen our management team as we continue to focus on additional opportunities to leverage our technology platforms and our dedicated dental and dermatology sales forces," stated Colin Stewart, president and chief executive officer of CollaGenex.
...
Brad will oversee our preclinical research and development efforts and play a leading role in protecting and expanding our intellectual property.
...
Bradley Zerler, PhD, as Vice President, Research
Dr. Zerler brings more than 15 years of research and development experience at domestic and international life sciences companies.He will work with Klaus Theobald, M.D., the Company's senior vice president and chief medical officer, to develop future products emerging from CollaGenex's proprietary drug development efforts.
Prior to re-joining CollaGenex, Dr. Zerler was Director of Biology for Locus Pharmaceuticals, Inc., a privately held pharmaceutical company focused on developing novel, small molecule therapeutic drugs.Dr. Zerler worked for CollaGenex from 1997 through 2001 as Director of Research, when the Company launched its flagship product, Periostat®, the first and only systemic treatment for adult periodontitis.Dr. Zerler initially joined CollaGenex from Bayer where he spent more than 10 years in its Biotechnology and Research divisions.


InterWest Partners - Investing in Information Technology & Life Sciences

www.interwest.com [cached]

Brad Zerler, VP of research at CollaGenex, agreed that care should be taken when directly targeting MMPs.

"MMPs play an important temporal role in wound healing and tissue remodeling," he said. "Consequently, there are times when inhibition may be appropriate; but there are times when the enzymes are required and, for those reasons, inhibition would be inappropriate. Therefore, inhibition of MMPs post-trauma may be quite tricky in regard to timing and needed tissue repair and remodeling."
Zerler said doxycycline is less potent than other MMPIs, which he said could account for the lower incidence of side effects. "Most in the field think of MMP inhibition in terms of treating chronic conditions, and perhaps that is why their development has been somewhat disappointing," he said. He proposed that treatment of acute, rather than chronic, pain "may just be the niche for this class of compounds."
But, Zerler added, the Nature Medicine paper "suggests that inhibition of downstream mediators such as IL-1 or perhaps p38 may be more appropriate targets for neuropathic pain."

Similar Profiles

Other People with this Name

Other people with the name Zerler

Janet Zerler
Berkshire Hathaway Alliance Real Estate

Marcia Zerler
St. Elizabeth Health Center

Holly Zerler
Wolcott LLC

David Zerler
Wolcott LLC

Mark Zerler
PLZ Aeroscience Corporation

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory